INSM vs. JAZZ: Insmed vs. Jazz Pharmaceuticals Stock Comparison

Company Profile

Insmed (INSM) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INSM is classified in Biotechnology while JAZZ is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Insmed (INSM) reports a negative ROE of -72.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Jazz Pharmaceuticals (JAZZ) reports 5.05%, ranking against industry peers normally.

Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile Jazz Pharmaceuticals (JAZZ) reports 4.37%, ranking against industry peers normally.

Insmed (INSM) reports a negative operating margin of -15.60%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Jazz Pharmaceuticals (JAZZ) reports 30.17%, ranking against industry peers normally.

Profitability Metrics

Growth

Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while Jazz Pharmaceuticals (JAZZ) at 4.88% is closer to the peer norm — faster top-line expansion for INSM.

Only one side can be read here: Jazz Pharmaceuticals (JAZZ) reports EPS growth of -167.51%, ranked against its industry; Insmed (INSM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Insmed (INSM) at 2.86 keeps current ratio within its industry’s typical mid-range, while Jazz Pharmaceuticals (JAZZ) at 1.82 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JAZZ.

Both Insmed (INSM) at 1.01 and Jazz Pharmaceuticals (JAZZ) at 1.35 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Neither Insmed (INSM) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Insmed (INSM) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Jazz Pharmaceuticals (JAZZ) trades at 69.46 times trailing earnings, ranked against its peers, while Insmed (INSM) has no P/E ratio this period.

On P/S ratio, both Insmed (INSM) at 16.52 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Jazz Pharmaceuticals (JAZZ) at 3.59 sits near its industry’s typical P/B ratio, while Insmed (INSM) at 34.55 prices above its benchmark range — INSM looks rich relative to book.

Valuation Metrics